Experienced in Frontotemporal Dementia

Shuichi Hironaka

Mitaka, JP 
Experienced in Frontotemporal Dementia
Mitaka, JP 
OverviewLocationsClinical Research

Overview

Shuichi Hironaka practices in Mitaka, Japan. Mr. Hironaka is rated as an Experienced expert by MediFind in the treatment of Frontotemporal Dementia. His top areas of expertise are Stomach Cancer, Esophageal Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, and Endoscopy.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Frontotemporal Dementia.

Gender
Male

Locations

Mitaka, Japan
Other Locations
Chuo, Japan
Tokyo, Japan
Saitama, Japan
Chiba, Japan
Hidaka, 3501298, Japan
Oita, Japan
Yufu, Japan
Shizuoka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3

92 Total Publications

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hironaka's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile